Windham Venture Partners was founded by Adam Fine, Roger Fine and Joe Proto.
Over the past decades, the team has built a reputation of trust, integrity and deep expertise in the healthcare industry. Windham Venture Partners believes the relationships with entrepreneurs and CEOs are as important as the investment itself.
Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at Coravin, GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University.
Roger Fine is a co-founder and Chairman of Windham Venture Partners. Roger retired as corporate vice president and general counsel of Johnson & Johnson (J&J) after a 30-year career with the company. He served as a member of the J&J Executive Committee for 15 years. Roger is the chairman of the board of trustees of the Robert Wood Johnson Foundation, the 3rd largest foundation in the U.S. and the largest foundation in the world devoted to healthcare. He is also chairman of the board of trustees of the Child Health Institute of New Jersey. Roger currently serves on the Business Advisory Board of Healthpoint Capital, a private equity fund in New York. He is also chairman of the Foundation Venture Capital Group, an in-house VC fund focused on commercializing discoveries made by scientific faculty at the Rutgers Medical School.
Roger graduated from Columbia University and earned his law degree from New York University School of Law.
Joe Proto became Chairman and Chief Executive Officer of Transactis Inc. in 2007, after nearly three decades in the billing and payments industry as a senior executive and successful entrepreneur. Prior to Transactis, he launched REMITCO, a remittance processing company, which was acquired in 2000 by First Data Corp, as well as Financial Telesis (CashFlex), which was acquired in 1992 by CoreStates, now part of Wells Fargo. Joe recently joined the Board of Directors of BillMyParents and is also an LP and Advisor in Metamorphic Ventures (focused on transactional media). Joe is a member of various financial services associations and has been a frequent speaker at conferences in the payments industry.
Lorne Taichman is Director, Science & Technology at Windham Venture Partners. Lorne has an MD degree from the University of Toronto and a PhD in Molecular Biology from the University of Wisconsin. Lorne is a professor emeritus at Stony Brook University where he directed a medical research laboratory for 30 years. His field of study was stem cells and gene and cell therapy. He has authored over 60 peer-reviewed publications and, in addition, was the recipient of an NIH MERIT award. In 2000, Lorne spent a sabbatical year at Johnson & Johnson’s Corporate Office of Science and Technology where he evaluated emerging technologies. Lorne remained as a part-time consultant to COSAT and in 2007 he left the University to join Windham. As Windham’s Director of Science & Technology, Lorne assists in locating new technologies for our review and in critically assessing the opportunity they present.
Kush Mody is an Associate at Windham Venture Partners. Prior to Windham, Kush was a venture associate at the Columbia Lab-to-Market Accelerator and an intern in the emergency, trauma, and acute care unit at World Health Organization. Previously, he has also served as VP of expansion at Sling Health and built an app to help emergency physicians better assess children with potential cervical spine injuries. Kush has conducted clinical research primarily related to orthopaedic surgery and has been published numerous times in leading journals. Currently, Kush is in his final year of an accelerated 7-year BS/MD program at Drexel University and pursuing an MBA at Columbia Business School.
Kaylin Collins is the Operations Associate at Windham Venture Partners. Prior to Windham, Kaylin was the Office Manager and Executive Assistant at Interior Marketing Group, a luxury real estate design and marketing firm. Kaylin directly supported the CEO and executive management team.
Kaylin received her BA from the University of Hartford in Hartford, CT.
Windham is building an Advisory Board comprised of business leaders, scientists, clinicians, entrepreneurs and fund managers from the healthcare industry.
Jason is the Founder of and Chief Solutions Officer for Helgerson Solutions Group, a health care consultancy firm focused on helping organizations successfully transition to a value based world. HSG works with private companies, governments and non-profit organization that need assistance in implementing value-based payment approaches and new care models that will lead to improved patient outcomes and lower overall costs. HSG is also a trusted advisor for private equity and venture capital firms as they look for new investment opportunities and work with companies to drive growth and profitability.
Prior to founding HSG, Jason was New York’s Medicaid Director. Jason ran the $70 billion program for over 7 years and was recognized as one of the nation’s most effective healthcare leaders. Prior to New York, Jason was Wisconsin’s Medicaid Director where he lead the state’s nationally recognized Badgercare Plus program. When Jason left public service and founded HSG he was the nation’s longest standing Medicaid Director.
Deneen Vojta, MD is an Executive Vice President for Research and Development at UnitedHealth Group, where she leads Global Research and Development. Prior to UnitedHealth, Dr. Vojta was the Founder and CEO of MYnetico / Alliance Health Solutions, as well as the Chief Medical Officer at Health Partners and Frankford Health.
Dr. Vojta has served as a board member of non-profit health care institutions and earned numerous federal and foundation grants to investigate complex health care concerns. She is widely published and frequently invited to speak on a number of health issues.
Dr. Vojta received her BS in Behavioral Neurosciences at the University of Pittsburgh, and an MD from Temple University School of Medicine
Allan Bufferd was the Chief Investment Officer of MIT for 19 years and has served as its Treasurer Emeritus since his retirement in May 2006. He also serves as Director and Treasurer at Beth Israel Deaconess Medical Center and is a Trustee & Investment Committee Chair at both the RW Johnson Foundation and the Boston Children’s Hospital.
Dr. Bufferd holds his S.B, S.M. and Sc.D. degrees in materials engineering from MIT and a J.D. from Suffolk University.
Alistair Erskine, MD is Chief Digital Health Officer for Partners Healthcare. Prior to Partners, Dr. Erskine served as Chief Informatics Officer at the Geisinger Health System. Dr. Erskine led the Division of Informatics which engaged staff in the design and configuration of Geisinger’s clinical information systems and evolved Geisinger’s facilities to take advantage of ultramodern technologies. Prior to Geisinger, Dr. Erskine was Associate Dean of Medical Informatics at Virginia Commonwealth University and was member of the Board for the 650-physician Medical College of Physician practice plan. He was appointed to the Virginia Governor’s Health Information Technology Commission by Executive Order and was a voting member of the Health Information Technology Standards Committee. Dr. Erskine presents and publishes on the topic of clinical transformation in peer-reviewed literature. Dr. Erskine trained at Brown University and Virginia Commonwealth University Health System and is triple Board-Certified in Internal Medicine, Clinical Informatics and Pediatrics. He has been practicing hospital medicine for 15 years. He is currently engaged in a two-year program with MIT Sloan School of Management, with a specialization in Business Analytics and Artificial Intelligence. He earned his MBA from the MIT Sloan School of Management, with a specialization in Business Analytics and Artificial Intelligence
Bill is a retired Managing General Partner of Healthcare Ventures, which led the strategic development and management of more than 100 companies with a combined market capitalization of more than $60 billion. Examples of HealthCare Ventures companies include Human Genome Sciences, MedImmune (acquired by Astra Zeneca), Novazyme (acquired by Genzyme), Shire, Dendreon, and FoldRx, (acquired by Pfizer). Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International from 1987 to 1993. Bill currently serves on the Board of Directors for The Medicines Company, and 4 private biotech companies.
Jeffrey A. Sachs is a leading health care policy expert who has worked with federal and state governments, hospitals, health systems, health plans, behavioral health organizations, technology companies, unions and others for more than three decades. He is also the Founder of Sachs Policy Group, a consulting firm that advises health care leaders on relevant local and national healthcare policy.
Riccardo Braglia is the first member of our Advisory Board. Riccardo is CEO of Helsinn Holding SA, a $350mm+ Swiss specialty pharmaceutical firm focusing on supportive cancer care. He comes with 27 years experience in licensing deals. In 2011 Riccardo received the Ernst & Young award for the three best Swiss entrepreneurs in the High Tech/Life Sciences category. Riccardo received the Award of Ernst & Young Entrepreneur of the Year 2012 in Switzerland in the category of Industry/technology/life sciences.
Windham Venture Partners has partnered with Greenspring Associates to provide back office infrastructure and fund administration.
Eric Thompson, COO, GreenSpring Associates; Windham Fund Administration
Eric Thompson is the Chief Operating Officer of Greenspring Back Office Solutions (GBOS), which provides outsourced fund administration services to Windham. GBOS is a related entity of Greenspring Associates, a global venture capital fund with over $8.8 billion in assets under management.
Lindsay Redfield, CFO, GreenSpring Associates; Windham Fund Administration
Lindsay Redfield is the Chief Financial Officer of Greenspring Back Office Solutions (GBOS), which provides outsourced fund administration services to Windham. GBOS is a related entity of Greenspring Associates, a global venture capital fund with over $8.8 billion in assets under management.
Julieanna Wiley, Controller, GreenSpring Associates; Windham Fund Administration
Julieanna Wiley is the Controller of Greenspring Back Office Solutions (GBOS), which provides outsourced fund administration services to Windham. GBOS is a related entity of Greenspring Associates, a global venture capital fund with over $8.8 billion in assets under management
